Gyre Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Gyre Therapeutics, Inc. (GYRE) reported Net Income (Loss) Available to Common Stockholders, Basic of -$11.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-07
- Gyre Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$11.66M.
- Gyre Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$8.69M, a 422.13% decline year-over-year.
- Gyre Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$1.72M.
- Gyre Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was $3.61M, a 221.17% increase year-over-year.
- Gyre Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was $5.03M, a 58.40% decline from fiscal 2024.
- Gyre Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was $12.09M.
- Gyre Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$92.93M, a 4137.05% decline from fiscal 2022.
- Gyre Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was $2.30M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$11.66M 10-Q · filed 2026-08-07 | -$24.81M 10-Q · filed 2026-08-07 | -$22.08M derived: sum of 3 quarters · filed 2026-08-07 | -$18.47M derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2026-03-31 | -$8.69M 10-Q · filed 2026-05-08 | -$10.41M derived: sum of 2 quarters · filed 2026-05-08 | -$6.80M derived: sum of 3 quarters · filed 2026-05-08 | -$8.85M derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2025-12-31 | -$1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $1.89M derived: sum of 2 quarters · filed 2026-03-13 | -$157.00K derived: sum of 3 quarters · filed 2026-08-07 | $5.03M 10-K · filed 2026-03-13 | |||
| 2025-09-30 | $3.61M 10-Q · filed 2025-11-07 | $1.57M derived: sum of 2 quarters · filed 2026-08-07 | $6.75M 10-Q · filed 2025-11-07 | $4.17M derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2025-06-30 | -$2.04M 10-Q · filed 2026-08-07 | $442.00K 10-Q · filed 2025-08-11 | $126.00K 10-Q · filed 2026-08-07 | $3.14M 10-Q · filed 2025-08-11 | $555.00K derived: sum of 3 quarters · filed 2026-08-07 | $1.68M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-03-31 | $2.70M 10-Q · filed 2026-05-08 | $2.60M derived: sum of 2 quarters · filed 2026-05-08 | $3.72M derived: sum of 3 quarters · filed 2026-05-08 | $7.25M derived: sum of 4 quarters · filed 2026-05-08 | |||
| 2024-12-31 | -$99.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $1.02M derived: sum of 2 quarters · filed 2026-03-13 | $4.55M derived: sum of 3 quarters · filed 2026-03-13 | $12.09M 10-K · filed 2026-03-13 | |||
| 2024-09-30 | $1.12M 10-Q · filed 2025-11-07 | $4.65M derived: sum of 2 quarters · filed 2025-11-07 | $12.18M 10-Q · filed 2025-11-07 | -$88.82M derived: sum of 4 quarters · filed 2025-11-07 | |||
| 2024-06-30 | $3.53M 10-Q · filed 2025-08-11 | $11.06M 10-Q · filed 2025-08-11 | -$89.95M derived: sum of 3 quarters · filed 2025-08-11 | -$85.97M derived: sum of 4 quarters · filed 2025-08-11 | |||
| 2024-03-31 | $7.53M 10-Q · filed 2025-05-09 | -$93.47M derived: sum of 2 quarters · filed 2025-05-09 | -$89.50M derived: sum of 3 quarters · filed 2025-05-09 | -$87.64M derived: sum of 4 quarters · filed 2025-05-09 | |||
| 2023-12-31 | -$101.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$97.03M derived: sum of 2 quarters · filed 2025-03-17 | -$95.18M derived: sum of 3 quarters · filed 2025-03-17 | -$92.93M 10-K · filed 2025-03-17 | |||
| 2023-09-30 | $3.98M 10-Q · filed 2024-11-13 | -$1.58M 10-Q · filed 2023-10-26 | $5.83M derived: sum of 2 quarters · filed 2024-11-13 | $8.07M 10-Q · filed 2024-11-13 | -$3.79M 10-Q · filed 2023-10-26 | -$21.84M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $1.85M 10-Q · filed 2024-08-13 | -$2.47M 10-Q · filed 2023-08-14 | $4.10M 10-Q · filed 2024-08-13 | -$2.21M 10-Q · filed 2023-08-14 | -$25.81M derived: sum of 3 quarters · filed 2024-08-13 | -$30.70M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $2.24M 10-Q · filed 2024-05-13 | $260.00K 10-Q · filed 2023-05-15 | -$27.67M derived: sum of 2 quarters · filed 2024-05-13 | -$32.55M derived: sum of 3 quarters · filed 2024-05-13 | $19.08M derived: sum of 4 quarters · filed 2024-05-13 | ||
| 2022-12-31 | -$29.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$34.79M derived: sum of 2 quarters · filed 2024-03-27 | $16.84M derived: sum of 3 quarters · filed 2024-03-27 | $2.30M 10-K · filed 2024-03-27 | |||
| 2022-09-30 | -$4.88M 10-Q · filed 2023-10-26 | $46.75M derived: sum of 2 quarters · filed 2023-10-26 | $32.21M 10-Q · filed 2023-10-26 | ||||
| 2022-06-30 | $51.63M 10-Q · filed 2023-08-14 | $37.10M 10-Q · filed 2023-08-14 | |||||
| 2022-03-31 | -$14.54M 10-Q · filed 2023-05-15 | ||||||
| 2021-09-30 | -$25.24M 10-Q · filed 2022-11-14 | -$45.17M derived: sum of 2 quarters · filed 2022-11-14 | -$67.60M 10-Q · filed 2022-11-14 | -$86.51M derived: sum of 4 quarters · filed 2022-11-14 | |||
| 2021-06-30 | -$19.93M 10-Q · filed 2022-08-15 | -$42.37M 10-Q · filed 2022-08-15 | -$61.27M derived: sum of 3 quarters · filed 2022-08-15 | -$77.31M derived: sum of 4 quarters · filed 2022-08-15 | |||
| 2021-03-31 | -$22.44M 10-Q · filed 2021-05-06 | -$41.34M derived: sum of 2 quarters · filed 2021-05-06 | -$57.38M derived: sum of 3 quarters · filed 2021-05-06 | -$74.63M derived: sum of 4 quarters · filed 2021-08-05 | |||
| 2020-12-31 | -$18.91M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | -$34.94M derived: sum of 2 quarters · filed 2021-03-04 | -$52.19M derived: sum of 3 quarters · filed 2021-08-05 | -$56.24M 10-K · filed 2021-03-04 | |||
| 2020-09-30 | -$16.03M 10-Q · filed 2020-11-05 | -$33.28M derived: sum of 2 quarters · filed 2021-08-05 | -$37.33M 10-Q · filed 2020-11-05 | -$50.94M derived: sum of 4 quarters · filed 2021-08-05 | |||
| 2020-06-30 | -$17.25M 10-Q · filed 2021-08-05 | -$21.30M 10-Q · filed 2021-08-05 | -$34.91M derived: sum of 3 quarters · filed 2021-08-05 | -$47.62M derived: sum of 4 quarters · filed 2021-08-05 | |||
| 2020-03-31 | -$4.05M 10-Q · filed 2021-05-06 | -$17.66M derived: sum of 2 quarters · filed 2021-05-06 | -$30.37M derived: sum of 3 quarters · filed 2021-05-06 | -$44.15M derived: sum of 4 quarters · filed 2021-05-06 | |||
| 2019-12-31 | -$13.61M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | -$26.32M derived: sum of 2 quarters · filed 2021-03-04 | -$40.10M derived: sum of 3 quarters · filed 2021-03-04 | -$55.18M 10-K · filed 2021-03-04 | |||
| 2019-09-30 | -$12.71M 10-Q · filed 2020-11-05 | -$26.49M derived: sum of 2 quarters · filed 2020-11-05 | -$41.57M 10-Q · filed 2020-11-05 | -$52.41M derived: sum of 4 quarters · filed 2020-11-05 | |||
| 2019-06-30 | -$13.78M 10-Q · filed 2020-08-06 | -$28.86M 10-Q · filed 2020-08-06 | -$39.70M derived: sum of 3 quarters · filed 2020-08-06 | -$47.39M derived: sum of 4 quarters · filed 2020-08-06 | |||
| 2019-03-31 | -$15.08M 10-Q · filed 2020-05-11 | -$25.92M derived: sum of 2 quarters · filed 2020-05-11 | -$33.61M derived: sum of 3 quarters · filed 2020-05-11 | -$40.10M derived: sum of 4 quarters · filed 2020-05-11 | |||
| 2018-12-31 | -$10.84M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-20 | -$18.53M derived: sum of 2 quarters · filed 2020-02-20 | -$25.01M derived: sum of 3 quarters · filed 2020-02-20 | -$30.05M 10-K · filed 2020-02-20 | |||
| 2018-09-30 | -$7.69M 10-Q · filed 2019-11-07 | -$14.18M derived: sum of 2 quarters · filed 2019-11-07 | -$19.22M 10-Q · filed 2019-11-07 | -$24.97M derived: sum of 4 quarters · filed 2019-11-07 | |||
| 2018-06-30 | -$6.48M 10-Q · filed 2019-08-01 | -$11.52M 10-Q · filed 2019-08-01 | -$17.28M derived: sum of 3 quarters · filed 2019-08-01 | -$23.07M derived: sum of 4 quarters · filed 2019-08-01 | |||
| 2018-03-31 | -$5.04M 10-Q · filed 2019-05-02 | -$10.79M derived: sum of 2 quarters · filed 2019-05-02 | -$16.59M derived: sum of 3 quarters · filed 2019-05-02 | -$26.42M derived: sum of 4 quarters · filed 2019-05-02 | |||
| 2017-12-31 | -$5.75M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | -$11.55M derived: sum of 2 quarters · filed 2019-03-08 | -$21.37M derived: sum of 3 quarters · filed 2019-03-08 | -$25.51M 10-K · filed 2019-03-08 | |||
| 2017-09-30 | -$5.79M 10-Q · filed 2018-11-01 | -$15.62M derived: sum of 2 quarters · filed 2018-11-01 | -$19.76M 10-Q · filed 2018-11-01 | -$23.51M derived: sum of 4 quarters · filed 2018-11-01 | |||
| 2017-06-30 | -$9.83M 10-Q · filed 2018-08-02 | -$13.97M 10-Q · filed 2018-08-02 | -$17.72M derived: sum of 3 quarters · filed 2018-08-02 | -$22.49M derived: sum of 4 quarters · filed 2018-08-02 | |||
| 2017-03-31 | -$4.14M 10-Q · filed 2018-05-03 | -$7.89M derived: sum of 2 quarters · filed 2018-05-03 | -$12.66M derived: sum of 3 quarters · filed 2018-05-03 | -$17.49M derived: sum of 4 quarters · filed 2018-05-03 | |||
| 2016-12-31 | -$3.75M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-19 | -$8.52M derived: sum of 2 quarters · filed 2018-03-19 | -$13.35M derived: sum of 3 quarters · filed 2018-03-19 | -$16.95M 10-K · filed 2018-03-19 | |||
| 2016-09-30 | -$4.77M 10-Q · filed 2017-11-02 | -$9.60M derived: sum of 2 quarters · filed 2017-11-02 | -$13.20M 10-Q · filed 2017-11-02 | ||||
| 2016-06-30 | -$4.83M 10-Q · filed 2017-08-03 | -$8.42M 10-Q · filed 2017-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |